오피오이드 사용 장애(OUD) 시장 규모, 점유율, 성장 및 세계 산업 분석 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별 인사이트와 예측(2025-2034년)

Growth Factors of Opioid Use Disorder (OUD) Market

The global Opioid Use Disorder (OUD) market size was valued at USD 3.92 billion in 2025 and is projected to reach USD 4.26 billion in 2026, further expanding to USD 9.27 billion by 2034. Market expansion is driven by increasing opioid addiction prevalence, rising government intervention programs, and growing availability of medication-assisted treatment options. In 2025, North America dominated the global market with a share of 77.59%, supported by high disease prevalence and strong public healthcare funding.

Opioid Use Disorder is a chronic medical condition characterized by compulsive opioid use despite harmful consequences. Approved medications for treatment include buprenorphine, methadone, and naltrexone, which are regulated therapies authorized for reducing withdrawal symptoms, relapse risk, and overdose mortality. Rising prescription rates for opioid-based pain medications for chronic diseases continue to contribute to dependency risks, thereby increasing the demand for long-term treatment solutions.

Market Growth Factors

The growing incidence of opioid addiction remains a major growth driver for the OUD market. Chronic pain conditions related to cancer, orthopedic disorders, and post-surgical recovery often require opioid-based analgesics, which increase long-term dependency risks. Global drug usage statistics indicate a steady rise in opioid exposure, contributing to higher OUD diagnosis rates and treatment demand.

In the U.S., approximately 2.7 million individuals were affected by OUD in 2021, driving strong utilization of medication-assisted treatment programs. Increased government spending on substance abuse prevention and treatment programs is also supporting drug accessibility and insurance reimbursement for OUD medications. Funding initiatives are expanding opioid treatment programs and increasing availability of clinic-based therapies, especially injectable long-acting formulations.

Market Restraints

Adverse effects associated with OUD medications may restrict treatment adherence and market growth. Common side effects include nausea, constipation, respiratory depression, muscle pain, and psychological symptoms. Regulatory warnings regarding dental complications associated with buprenorphine oral formulations have also impacted patient confidence. Safety concerns may delay therapy initiation or reduce long-term compliance, particularly in patients with pre-existing medical conditions.

In addition, social stigma related to substance abuse disorders remains a barrier to seeking timely medical care, especially in developing regions, limiting diagnosis rates and reducing treatment penetration.

Market Trends

A key trend in the market is the increasing adoption of buprenorphine transdermal and long-acting injectable therapies, which improve compliance by reducing daily dosing requirements. These formulations offer steady drug delivery and lower relapse risks, making them suitable for long-term outpatient management. Growing investments in extended-release formulations and depot injections are expanding therapeutic options for patients requiring continuous opioid dependence control.

Digital therapy platforms and telemedicine integration are also gaining attention, supporting behavioral counseling alongside pharmacological treatment and improving patient engagement in recovery programs.

Segmentation Analysis

By Drug Class

The market is segmented into buprenorphine, methadone, and naltrexone. The buprenorphine segment dominated the market with a share of 83.24% in 2026, driven by high clinical acceptance and multiple branded drug formulations. Products such as SUBLOCADE, SUBOXONE, and ZUBSOLV support long-term treatment strategies and are widely prescribed in developed markets.

Methadone holds a smaller share due to increased generic availability and regulatory restrictions on clinic-based distribution. Naltrexone adoption remains limited due to fewer available formulations and lower physician preference for first-line therapy.

By Route of Administration

Based on route of administration, the market is categorized into oral and parenteral. The parenteral segment accounted for 84.65% market share in 2026, supported by widespread use of injectable depot therapies that ensure consistent drug exposure and reduce misuse risks. Oral formulations continue to grow steadily due to patient convenience and outpatient treatment flexibility.

By Distribution Channel

Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominated with a 46.19% share in 2026, as injectable therapies are typically administered through supervised treatment programs. Retail pharmacies remain critical for oral medication dispensing, while online pharmacies are expanding due to convenience and privacy benefits.

Regional Outlook

North America remained the largest regional market with USD 3.04 billion in 2025, supported by high addiction prevalence and extensive treatment infrastructure. The U.S. market reached USD 3.04 billion by 2026, driven by strong reimbursement policies and federal funding programs.

Europe ranks second, supported by rising adoption of buprenorphine therapies. By 2026, the U.K. market was valued at USD 0.09 billion, while Germany reached USD 0.07 billion. Asia Pacific shows strong growth momentum, with increasing healthcare spending and awareness campaigns. By 2026, China reached USD 0.10 billion, Japan USD 0.08 billion, and India USD 0.05 billion. Latin America and Middle East & Africa continue to expand due to rising diagnosis rates and healthcare investments.

Competitive Landscape

The market is dominated by Indivior PLC, Alkermes, and Orexo AB, which together hold a significant market share through extensive buprenorphine and naltrexone portfolios. These companies focus on long-acting injectable therapies, improved delivery platforms, and regulatory approvals to expand treatment accessibility.

Other notable players include Titan Pharmaceuticals, Mallinckrodt Pharmaceuticals, Viatris, Hikma Pharmaceuticals, and Camurus, which are investing in extended-release technologies and novel drug delivery systems to improve patient adherence.

Report Coverage

The report provides detailed analysis of market size and value for 2025, 2026, and 2034, along with segmentation by drug class, route of administration, and distribution channel. It includes regional market evaluation across North America, Europe, Asia Pacific, and the rest of the world, with country-level market values for major economies. The study examines industry developments, regulatory approvals, product launches, partnerships, and clinical innovation trends shaping the global opioid use disorder treatment landscape.

Conclusion

The Opioid Use Disorder (OUD) market is positioned for strong expansion from USD 3.92 billion in 2025 to USD 4.26 billion in 2026, reaching USD 9.27 billion by 2034, reflecting the growing global burden of opioid dependency and the rising demand for structured, medication-assisted treatment programs. High disease prevalence, particularly in North America with a 77.59% market share in 2025, continues to shape treatment adoption patterns, supported by strong reimbursement frameworks and large-scale government funding initiatives focused on substance abuse prevention and recovery.

Buprenorphine remains the dominant drug class, accounting for 83.24% market share in 2026, driven by the availability of multiple branded formulations and increasing preference for long-acting injectable and transdermal delivery systems that improve treatment adherence and reduce relapse risks. The dominance of the parenteral route with 84.65% share in 2026 highlights the clinical preference for supervised, long-acting therapies in structured treatment settings, while hospital pharmacies maintaining 46.19% share in 2026 reflects the central role of opioid treatment programs and inpatient care facilities in administering these medications.

Regionally, North America continues to lead due to high diagnosis rates and well-established treatment infrastructure, while Europe benefits from expanding product approvals and strong adoption of buprenorphine-based therapies. Asia Pacific is emerging as a high-growth region due to increasing healthcare expenditure, improving access to addiction treatment services, and rising public awareness initiatives in countries such as China, Japan, and India. Latin America and the Middle East & Africa are also gradually expanding as healthcare access and policy attention toward substance abuse disorders increase.

Competitive dynamics remain driven by innovation in drug delivery platforms, long-acting formulations, and digital treatment support models. Market leaders such as Indivior, Alkermes, and Orexo continue to strengthen their portfolios through R&D investments, regulatory approvals, and strategic collaborations, while other manufacturers focus on extended-release technologies and improved patient compliance solutions. Ongoing advancements in formulation science, coupled with supportive policy frameworks and expanding treatment coverage, are expected to sustain long-term growth across institutional and outpatient treatment settings worldwide.

Segmentation By Drug Class

• Buprenorphine
• Methadone
• Naltrexone

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Stores
• Online Pharmacies

By Region

• North America (By Drug Class, By Route of Administration, By Distribution Channel, By Country)
  • U.S.
  • Canada
• Europe (By Drug Class, By Route of Administration, By Distribution Channel, By Country/sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, By Route of Administration, By Distribution Channel, By Country/sub-region)
  • Japan
  • China
  • India
  • Australia
  • South East Asia
  • Rest of Asia Pacific
• Rest of the World (By Drug Class, By Route of Administration, By Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Pipeline Analysis, Key Products
• 4.2. New Product Launches
• 4.3. Statistics of Opioid Use Disorder by Key Countries/Region
• 4.4. Industry Developments Such as Mergers, Acquisitions, and Collaborations
• 4.5. Impact of COVID-19 on Opioid Use Disorder (OUD) Market

5. Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Buprenorphine
  • 5.1.2. Methadone
  • 5.1.3. Naltrexone
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Parenteral
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospitals Pharmacies
  • 5.3.2. Retail Pharmacies & Stores
  • 5.3.3. Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Buprenorphine
  • 6.1.2. Methadone
  • 6.1.3. Naltrexone
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Parenteral
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospitals Pharmacies
  • 6.3.2. Retail Pharmacies & Stores
  • 6.3.3. Online Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Buprenorphine
  • 7.1.2. Methadone
  • 7.1.3. Naltrexone
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospitals Pharmacies
  • 7.3.2. Retail Pharmacies & Stores
  • 7.3.3. Online Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Buprenorphine
  • 8.1.2. Methadone
  • 8.1.3. Naltrexone
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Parenteral
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospitals Pharmacies
  • 8.3.2. Retail Pharmacies & Stores
  • 8.3.3. Online Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World Global Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Buprenorphine
  • 9.1.2. Methadone
  • 9.1.3. Naltrexone
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Parenteral
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospitals Pharmacies
  • 9.3.2. Retail Pharmacies & Stores
  • 9.3.3. Online Pharmacies

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Indivior PLC
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT analysis
    • 10.2.1.4. Recent developments
    • 10.2.1.5. strategies
    • 10.2.1.6. financials (based on availability)
  • 10.2.2. Alkermes
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT analysis
    • 10.2.2.4. Recent developments
    • 10.2.2.5. strategies
    • 10.2.2.6. financials (based on availability)
  • 10.2.3. Orexo US, Inc.
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT analysis
    • 10.2.3.4. Recent developments
    • 10.2.3.5. strategies
    • 10.2.3.6. financials (based on availability)
  • 10.2.4. Titan Pharmaceuticals Inc.
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT analysis
    • 10.2.4.4. Recent developments
    • 10.2.4.5. strategies
    • 10.2.4.6. financials (based on availability)
  • 10.2.5. Mallinckrodt
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT analysis
    • 10.2.5.4. Recent developments
    • 10.2.5.5. strategies
    • 10.2.5.6. financials (based on availability)
  • 10.2.6. BioDelivery Sciences International Inc.
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT analysis
    • 10.2.6.4. Recent developments
    • 10.2.6.5. strategies
    • 10.2.6.6. financials (based on availability)
  • 10.2.7. Viatris (Mylan N.V.)
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. SWOT analysis
    • 10.2.7.4. Recent developments
    • 10.2.7.5. strategies
    • 10.2.7.6. financials (based on availability)
  • 10.2.8. Hikma Pharmaceuticals
    • 10.2.8.1. Overview
    • 10.2.8.2. Products
    • 10.2.8.3. SWOT analysis
    • 10.2.8.4. Recent developments
    • 10.2.8.5. strategies
    • 10.2.8.6. financials (based on availability)
  • 10.2.9. Camurus
    • 10.2.9.1. Overview
    • 10.2.9.2. Products
    • 10.2.9.3. SWOT analysis
    • 10.2.9.4. Recent developments
    • 10.2.9.5. strategies
    • 10.2.9.6. financials (based on availability)
  • 10.2.10. Braeburn Inc.
    • 10.2.10.1. Overview
    • 10.2.10.2. Products
    • 10.2.10.3. SWOT analysis
    • 10.2.10.4. Recent developments
    • 10.2.10.5. strategies
    • 10.2.10.6. financials (based on availability)